Formula I Kinase Inhibitors for Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current p38 kinase inhibitors for treating excessive cytokine production are costly and face bioavailability and absorption issues, limiting their therapeutic effectiveness.
Innovation Solution
Development of new small molecule compounds, specifically those of Formula I, which act as potent inhibitors of p38 kinase with improved bioavailability and efficacy for suppressing the production of TNFα and IL-1β, thereby treating inflammatory and cardiovascular disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing p38 kinase inhibitors are used, then cytokine production is suppressed, but bioavailability and absorption are poor
Solution Approach 1:
The patent modifies the chemical structure of p38 kinase inhibitors by changing molecular parameters such as introducing specific functional groups (urea, carbamate, amide linkages), varying substituent patterns (R1-R6 groups), and adjusting molecular weight and lipophilicity. These parameter changes improve oral bioavailability and absorption while maintaining kinase inhibitory activity, directly resolving the contradiction between therapeutic effectiveness and bioavailability.
2Reliability
If existing p38 kinase inhibitors are used, then cytokine production is suppressed, but production cost is high
Solution Approach 1:
The patent develops small molecule compounds with simplified chemical structures compared to existing inhibitors. These molecules use common pharmaceutical building blocks and can be synthesized through straightforward multi-step procedures, significantly reducing production costs while maintaining effective p38 kinase inhibition and cytokine suppression.
3Reliability
If existing p38 kinase inhibitors are used, then cytokine production is suppressed, but absorption is limited
Solution Approach 1:
The patent optimizes absorption by modifying key physicochemical parameters including molecular weight (keeping compounds within optimal ranges), lipophilicity (balancing LogP values), and hydrogen bonding capacity. The structural modifications enable better membrane permeability and oral absorption, directly addressing the absorption limitations of existing inhibitors.
Data Source
AI summary
The present invention provides kinase inhibitors of Formula (I). Wherein R1, R2, X and Z are as described herein, or a pharmaceutically acceptable salt thereof.